Abstract Nanjing Nuoyuan Medical Devices Co., Ltd. (Nuoyuan Medical) has successfully completed a Phase I clinical trial in China for its independently developed Class I new drug, Pemefolacianine, with positive outcomes. As an innovative fluorescent imaging agent targeting folate receptor alpha (FRα), Pemefolacianine demonstrated excellent safety and favorable pharmacokinetics. Adopting a dual-track development model of […] The post Class I New Drug Pemefolacianine Completes Phase I Clinic...
